“Delivery mechanisms are becoming as valuable as the drugs themselves”

"Delivery mechanisms are becoming as valuable as the drugs themselves."

The clinical difference between an oncology drug that works and one that reaches the tumor intact often comes down to delivery technology. That's where the licensing value is shifting.